• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Beam Therapeutics Selects Research Triangle Park, North Carolina, for Research and Production Campus

Beam Therapeutics, a biotechnology company developing precision medicines through DNA base editing, plans to build a manufacturing facility in Research Triangle Park, North Carolina. The project is expected to create 201 jobs.

Over a period of 5 years, Beam Therapeutics expects to invest $83 million in the facility, which will support clinical and commercial manufacturing for the company’s novel base editing programs.

“We believe investment in strategic manufacturing capabilities is an important component of fully realizing the power of our base editing technology and achieving our vision to provide life-long cures to patients suffering from serious diseases”, said John Evans, CEO of Beam Therapeutics. “Research Triangle Park is a thriving biopharmaceutical hub, providing significant access to the broad range of talent we will need to make this vision a reality.”

Beam Therapeutics’ project in North Carolina will be facilitated, in part, by a Job Development Investment Grant approved by the state’s Economic Investment Committee earlier today. Over the course of 12 years, the project is estimated to grow the state’s economy by $1.36 billion.

According to state officials, using a formula that takes into account the new tax revenues generated by the new jobs, the agreement authorizes the potential reimbursement to the company of up to $3,237,750, spread over 12 years. Payments for all JDIGs only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets. JDIG projects result in positive net tax revenue to the state treasury, even after taking into consideration the grant’s reimbursement payments to a given company.

"North Carolina is a leader in biotechnology, from the research in our labs to the state’s biomanufacturers,” said Governor Roy Cooper. “Companies like Beam Therapeutics’ work in developing precision medicines will help keep North Carolina on the cutting edge of this industry.”

"North Carolina has been a world leader in biotechnology for many years, but we’re not resting on our past accomplishments,” said North Carolina Commerce Secretary Anthony M. Copeland. “Beam Therapeutics joins a host of gene therapy companies that are keeping North Carolina at the forefront of this new frontier of medicine.”

State officials noted, because Beam Therapeutics chose a site in Durham County, classified by the state’s economic tier system as Tier 3, the company’s JDIG agreement also calls for moving as much as $1,079,250 into the state’s Industrial Development Fund – Utility Account. The Utility Account helps rural communities finance necessary infrastructure upgrades to attract future business. Even when new jobs are created in a Tier 3 county such as Durham, the new tax revenue generated through JDIG grants helps more economically challenged communities elsewhere in the state.

In addition to the North Carolina Department of Commerce and the Economic Development Partnership of N.C. other key partners on this project were; the North Carolina Community College System, the North Carolina Biotechnology Center, Durham County, and the Greater Durham Chamber of Commerce.

Exclusive Research